117 terminated. 117 Phase 1, 38 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 117 | Terminated 117 |
| Phase 2 | 38 | Terminated 38 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ATA3219 - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Atara Biotherapeutics | 1 | 2024-09-06 | 2026-03-11 |
| A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers PF-08046044/SGN-35C - Hodgkin Disease, Lymphoma, T-Cell, Peripheral | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 58 | 2024-05-28 | 2026-07-06 |
| A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers PF-08046045 - Lymphoma, T-Cell, Cutaneous, Hodgkin Disease | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 22 | 2024-02-29 | 2026-07-06 |
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 40 | 2023-08-30 | 2026-05-06 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) Loncastuximab Tesirine - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 5 | 2023-07-28 | 2026-07-20 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma Venetoclax, Tazemetostat - Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 1 | Terminated | Weill Medical College of Cornell University | 3 | 2023-06-07 | 2026-04-02 |
| A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies ONCT-808, Bridging Therapy - Relapsed/Refractory Aggressive B-Cell Malignancies | Phase 1 / Phase 2 | Terminated | Oncternal Therapeutics, Inc | 9 | 2023-05-09 | 2024-12-05 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies CNTY-101, IL-2, Lymphodepleting Chemotherapy - R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma | Phase 1 | Terminated | Century Therapeutics, Inc. | 28 | 2023-01-24 | 2025-12-18 |
| Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies BN301 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | BioNova Pharmaceuticals (Shanghai) LTD. | 9 | 2022-11-25 | 2024-02-21 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Relatlimab, Nivolumab - Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2022-09-13 | 2026-06-26 |
| Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL GDA-201 - Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Gamida Cell ltd | 13 | 2022-07-05 | 2025-03-25 |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma EZM0414 - Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Epizyme, Inc. | 13 | 2022-05-31 | 2025-06-22 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 54 | 2022-04-07 | 2025-06-09 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma GLPG5101 - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | Phase 1 / Phase 2 | Terminated | Lakefront Biotherapeutics NV | 130 | 2022-03-09 | 2026-06-30 |
Showing 20 of 117. Sign in to see all of them.
Lymphoma, Follicular (69) · Lymphoma, Mantle-Cell (63) · Lymphoma, Non-Hodgkin (62) · Leukemia, Lymphocytic, Chronic, B-Cell (54) · Burkitt Lymphoma (47) · Lymphoma, B-Cell, Marginal Zone (44) · Lymphoma (40) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (40) · Lymphoma, Large-Cell, Immunoblastic (30) · Hodgkin Disease (26) · Waldenstrom Macroglobulinemia (26) · Lymphoma, Large-Cell, Anaplastic (24) · Lymphoma, T-Cell, Cutaneous (22) · Multiple Myeloma (22)
Hemic and Lymphatic Diseases (117) · Neoplasms by Histologic Type (117) · Immune System Diseases (116) · Immunoproliferative Disorders (116) · Lymphatic Diseases (116) · Lymphoproliferative Disorders (116) · Neoplasms (105) · Lymphoma, B-Cell (103) · Lymphoma (77) · Pathologic Processes (69) · Pathological Conditions, Signs and Symptoms (69) · Disease Attributes (67) · Hematologic Diseases (66) · Leukemia, Lymphoid (58) · Chronic Disease (56)
Rituximab (26) · Cyclophosphamide (13) · Lenalidomide (8) · venetoclax (7) · Doxorubicin (6) · Gemcitabine (6) · Bortezomib (5) · Etoposide (5) · Prednisone (5) · Vincristine (5) · fludarabine phosphate (5) · Dexamethasone (4) · fludarabine (4) · ibrutinib (4) · tanespimycin (4)
National Cancer Institute (NCI) (15) · Fred Hutchinson Cancer Center (5) · Masonic Cancer Center, University of Minnesota (5) · Novartis Pharmaceuticals (4) · Pfizer (4) · ADC Therapeutics S.A. (3) · City of Hope Medical Center (3) · Northwestern University (3) · Seagen Inc. (3) · University of Medicine and Dentistry of New Jersey (3) · AbbVie (2) · Antengene Corporation (2) · Barbara Ann Karmanos Cancer Institute (2) · Case Comprehensive Cancer Center (2) · Epizyme, Inc. (2)
United States (103) · Spain (16) · France (13) · Italy (10) · Australia (9) · China (8) · Germany (8) · United Kingdom (8) · Belgium (7) · Canada (7) · South Korea (7) · Netherlands (6) · Israel (4) · Japan (4) · Denmark (3)
Ajay Gopal (3) · Roger Strair, MD, PhD (3) · Abhinav Deol, M.D. (2) · Jordan Gauthier (2) · Adam Petrich, MD (1) · Aditi Mehta, DO (1) · Andre Goy, MD (1) · Andres Forero-Torres, MD (1)
PMID 34515338, PMID 31527168, PMID 19139736, PMID 23256542, PMID 23393050, PMID 24241210, PMID 28903943, PMID 29141948, PMID 31471376, PMID 33171487, PMID 34398557, PMID 35136603, PMID 35732829, PMID 35835137, PMID 36821767, PMID 37237172, PMID 37385724, PMID 37903325, PMID 38517235, PMID 39705540, PMID 39793445, PMID 39820359, PMID 40184567, PMID 40809193, PMID 41536778, PMID 42660131
2018 (4), 2023 (4), 2016 (3), P30CA015704 (3), P30CA072720 (3), 2015 (2), 2019 (2), P01CA044991 (2), P30CA015083 (2), P30CA033572 (2), P30CA043703 (2), U01CA069912 (2), U01CA076576 (2), 2009 (1), 2017 (1)